A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC

Prostate Cancer Metastatic Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled Multicentre Phase II Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02378870
• Other study ID #: ODX-002
• Status: Terminated
• Phase: Phase 2
• First received: November 17, 2014
• Last updated: June 29, 2016
• Start date: January 2015
• Est. completion date: September 2015

Study information

• Verified date: June 2016
• Source: DexTech Medical AB
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Medical Products AgencyDenmark: Danish Health and Medicines Authority
• Study type: Interventional

Clinical Trial Summary

This phase IIb study is a randomized, double-blind, placebo-controlled multi-center study evaluating efficacy and tolerability of Osteodex of patients with metastatic castration resistant prostate cancer (CRPC). Osteodex is a poly-bisphosphonate containing three known substances; dextran, alendronate and guanidine.

The objective of the study is to evaluate the relative change of response markers to bone metabolism (B-ALP and S-P1NP) The following objectives will also be evaluated: overall survival, PSA response, other response markers related to bone metabolism (S-CTX and osteocalcin), safety, tolerability, pain and quality of life.

Description:

Males, diagnosed with CRPC, who fulfil the inclusion criteria and does not have any exclusion criteria, will be asked to participate in the study. The subject will be informed orally and in writing about the study procedures and give written informed consent, prior to study start. At the screening visit the following examinations are performed: Physical examination, medical history and concomitant medication. Heart rate, blood pressure, weight, height, body temperature and respiratory rate are measured. Blood samples are drawn and urine sample is collected. ECG is recorded. Bone scan and PET-CT are also performed. At the next visit, baseline, the subject is examined physically and heart rate, blood pressure, weight, body temperature and respiratory rate are measured, ECG is recorded, blood samples drawn and urine sample collected. FACT-P and EQ-5D-5L questionnaire are filled out by the subject. Adverse events and concomitant medication is documented and the first dose of the investigational product is given.

The subject is surveyed for 3 hours at the hospital.

The duration of the study for the individual subject will be approximately 30 weeks from screening to the follow-up visit 2 weeks after the last dose. Each subject will receive at least 7 doses and maximum 13 doses of investigational product.

A Data Monitoring Committee (DMC) will be designated and will be responsible to monitor/review all study related safety data. After review of safety data the DMC will provide recommendation as to whether the dose escalation can proceed as planned according to the protocol.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: September 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 years at the time of signing the informed consent form.

2. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate.

3. Failing or not tolerating docetaxel therapy or for other reasons not suitable for such therapy and failing subsequent therapy with abiraterone and/or enzalutamide.

4. Evidence of metastatic disease from bone scan (bone lesions) or other imaging modality.

5. Evidence of PSA progression in two consecutive determinations at minimum 1 week interval.

6. Castrate level of serum testosterone =1.7 nmol/L

7. Performance status ECOG 0-2

8. Laboratory requirements: Haematology: Neutrophils = 1.5 x 109/l Hemoglobin = 90 g/l Platelets = 100 x 109/l Hepatic function: Total S-bilirubin = 1.5 times the upper limit of normal (ULN) AST (SGOT) / ALT (SGPT) = 2.5 times ULN Renal function: S-creatinine = 1.5 times the upper limit of normal (ULN) Electrolytes: S-sodium, S-potassium, S-calcium (S-albumin corrected), S-phosphate, S-magnesium, all within normal ranges.

9. No evidence (= 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin).

10. Able to adhere to the study visit schedule and other protocol requirements.

11. Life expectancy =6 months

Exclusion Criteria:

1. Concurrent use of other anti-cancer agents or treatments, with the following exception: a stable dose of LHRH agonist/antagonist or polyestradiol phosphate bicalutamide. Washout period bicalutamide 6 weeks; after flutamide 4 weeks; abiraterone / enzalutamide 6 weeks.

2. Any treatment modalities involving chemotherapy, radiation or major surgery within 4 weeks prior to treatment in this study.

3. Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 4 weeks prior to start of study treatment.

4. Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he participates in the study.

5. Plasma glucose level =7 mmol/l (or >120 mg/dl) at screening.

6. Known brain metastases.

7. Dental surgery (dental extraction), periodontal disease, local trauma including poorly fitting dentures within 6 months prior to the first dose of study drug.

8. Treatment with bisphosphonates within 4 weeks prior to first dose of study medication.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer Metastatic
• Prostatic Neoplasms

Intervention

Drug:
• Osteodex
Osteodex 3.0 mg/kg given every two week, maximum 13 times.
• Placebo

Locations

Country	Name	City	State
Sweden	Oncology clinic, Norrlands Universitetssjukhus	Umeå

Sponsors (1)

Lead Sponsor	Collaborator
DexTech Medical AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative change in response markers related to bone metabolism (B-ALP and S-P1NP)		Baseline and 24 weeks of treatment	No
Secondary	Relative change in response markers related to bone metabolism (B-ALP and S-P1NP)		Baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 weeks of treatment and at 2 weeks post-treatment.	No
Secondary	Relative change in response markers related to bone metabolism (S-CTX and osteocalcin)		Baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks of treatment and at 2 weeks post-treatment.	No
Secondary	PSA response		Baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks of treatment and at 2 weeks post-treatment.	No
Secondary	Overall survival	Life expectancy for participating subjects = 6 months	Baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks of treatment and at 2 weeks post-treatment. Long-term follow-up will be conducted every 3rd month, up to 12 months.	No
Secondary	Pain	FACT-P questionnaire	Baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks of treatment and at 2 weeks post-treatment.	No
Secondary	Analgesic consumption	Life expectancy for participating subjects = 6 months	Baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks of treatment and at 2 weeks post-treatment. Long-term follow-up will be conducted every 3rd month, up to 12 months.	No
Secondary	Changes in tumor cell metabolism measured	PET-CT	Baseline, 12 and 24 weeks of treatment	No
Secondary	Changes in bone metastasis	Bone scan	Baseline, 12 and 24 weeks of treatment	No
Secondary	Incidence, causality and intensity of AEs	Life expectancy for participating subjects = 6 months	Baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks of treatment and at 2 weeks post-treatment. Long-term follow-up will be conducted every 3rd month, up to 12 months	Yes
Secondary	Dose and duration of medications required for the treatment of AEs		Baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks of treatment and at 2 weeks post-treatment. Long-term follow-up will be conducted every 3rd month, up to 12 months.	Yes
Secondary	Change from baseline in Quality of life	EQ-5D-5L questionnaire, FACT-P questionnaire	Baseline and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks of treatment and 2 weeks post-treatment.	No